Diving Into Uncharted Waters with Bold Moves
MoreBetter is stepping right into the murky, unpredictable world of longevity, peptide, and psychedelic therapies with a fresh initiative—the RWE Co-Investment Program. This isn't your run-of-the-mill study announcement; it's a gutsy leap into largely unexplored areas of patient-reported outcomes and real-world evidence.
A Program for Progress
So what's the program about? MoreBetter is throwing its research weight behind a series of longitudinal studies. They're putting their research platform and methodologies to work, ensuring data is captured from patients' real-life usage and not just from sterile clinical environments. With up to 10 studies in the pipeline over the next year, they're not exactly dipping their toes—it's more like a cannonball.
Therapies in Focus
These therapies are like the wild west of medicine. Ketamine, peptides like BPC-157, and psychedelics such as psilocybin and ibogaine are still largely uncharted terrain from a regulatory standpoint. You can't ignore that certain substances are walking a tightrope of legality and acceptance. Each state has its own rules, and MoreBetter's program doesn't shy away from these complexities.
More Than Lip Service
Kevin Provost, the CEO of MoreBetter, isn't just dishing out the usual corporate spiel. He emphasizes the significance of backing real-world data. "Longevity, peptide, and psychedelic therapies are in daily use, yet very little is measured about what patients experience over time," he states.
Data, the New Gold
Regulators are hungry for data, and MoreBetter is giving them exactly that by designing studies with stringent protocols and validated instruments. They're not claiming to cure anything, but by collecting patient-reported outcomes and linking them to health records, they're forging a path where science meets practical utility.
The intention here isn't to create a breakthrough in treatments, but to pile up data that can help decipher how these therapies are genuinely impacting lives.
The Intricacies of Collaboration
Participants aren't just randomly chosen. They need a well-defined product, a clear regimen, and a suitable research question to move into MoreBetter's next phase of research. They're lining up the right partners—be it pharmacies, telehealth providers, or state regulators.
What Lies Ahead
Regulations for these therapies are still like shifting sands under our feet. The FDA has specific warnings and interim policies, but MoreBetter is clearly in this for the long haul. They're not providing, prescribing, or administering any therapies themselves—only gathering the information that could potentially become catalytic once the rules settle.
Crunching Numbers, Not Making Claims
They've published 18 peer-reviewed papers and worked alongside 12 universities. While MoreBetter generates data, they’re not in the business of puffing up treatments as a magic bullet. They know better than to claim any safety or efficacy without solid evidence.
It's all about putting the pieces together to see the larger picture.
The Bigger Picture
As they set up for launches starting in the first quarter of 2027, this is a story of potential, opportunity, and the smart leveraging of data. It’s a compelling play in the fast-evolving field of healthcare, and it may just be the kind of strategic insight that investors will want their eyes on. MoreBetter aims to be a beacon for understanding in a rather fragmented landscape. But until there's more clarity from the regulators, investors should watch with cautious optimism.
